MYOS' Proprietary Muscle Building Technology Fortetropin:

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
MYOS' Proprietary Muscle Building Technology Fortetropin: Foundation for New Dietary Recommendations

CEDAR KNOLLS, NJ--(Marketwired - Oct 19, 2015) - MYOS Corporation ("MYOS" or the "Company") ( NASDAQ : MYOS ), an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve human muscle health and performance, highlights a new report from Credit Suisse on " Fat: the New Health Paradigm ," showing the importance of fat in our diet. For several decades, fat has been blamed for heart disease and the obesity epidemic. A review of the research during this time calls into question the role that fat plays on our overall health. Eggs in particular have been thought to be associated with increased cholesterol and increased risks of heart disease. A more thorough review of the research behind these claims has brought new insights into the overall health benefits and low risks associated with the consumption of eggs. This has translated into an increased demand from consumers for many products, especially eggs. The overall demand for fat will increase over the next few decades and in particular; the egg market is expected to grow at 4 to 5% per year for the next two decades.

At MYOS Corporation, our patented core ingredient, Fortetropin, is a proteo-lipid complex derived from fertilized chicken egg yolk. In addition to providing all the known benefits one derives from an egg yolk, Fortetropin has also been shown to increase muscle size and mass in a randomized double-blind placebo controlled clinical trial. The ability to provide an all-natural ingredient with the many health benefits of eggs in stabilized form that can be combined in a variety of products provides many unique opportunities for MYOS Corporation.

Robert J. Hariri, M.D., Ph.D., Chairman of the Board of MYOS, states, "The medical and scientific community are now confirming that fat in the proper forms is beneficial, in fact essential, for our overall health. We believe eggs and products derived from them, such as Fortetropin, will be an important part of our diet in the years to come." Hariri further commented, "In addition, our clinical research has shown that Fortetropin, even at doses three times that shown to be effective in building lean muscle mass, does not negatively alter serum lipid profiles."

Neerav D. Padliya, Ph.D., Vice President, Research Alliances at MYOS, commented, "Our research will continue to focus on the ability to identify the key proteins and lipids in eggs that effect muscle regulatory pathways and inflammation. In a recent clinical study that we performed with the University of Tampa, we demonstrated that the daily consumption of Fortetropin at a dose equivalent to that of three eggs did not lead to statistically significant changes in total cholesterol, HDL, LDL and triglycerides in the study subjects."

The team at MYOS has always recognized the beneficial core components of eggs on overall health and its effects on many disease states. New research into Fortetropin and its effects on health and disease will continue to be at the forefront of our strategy moving forward.

About MYOS Corporation

MYOS is an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and function essential to the management of sarcopenia, cachexia and degenerative muscle diseases. MYOS is the owner of Fortetropin®, the first clinically proven natural myostatin inhibitor. Myostatin is a natural regulatory protein, which inhibits muscle growth and recovery. Medical literature suggests that lowering myostatin levels has many potential health benefits including increased muscle mass, healthy weight management, improved energy levels, stimulation of muscle healing as well as treating sarcopenia, a condition of age-related loss of muscle mass. To discover why MYOS is known as "The Muscle Company,"™ visit www.myoscorp.com

About Rē Muscle Health™

The Rē Muscle Health™ series is the Company's first branded line of muscle health products. This unique line of all-natural, non-GMO products contain Fortetropin®, an egg-based, all natural myostatin inhibitor clinically proven to build healthy muscle. The Rē Muscle Health™ series can be ordered by visiting www.remusclehealth.com . MYOS believes that Fortetropin®, as well as future products it envisions, will redefine existing standards for muscle health. The Rē Muscle Health™ product line is owned and sold directly by the Company. www.remusclehealth.com

Forward-Looking Statements

Any statements in this release that are not historical facts are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to the successful continued research of Fortetropin® and its effects on myostatin inhibition, inflammatory cytokine levels and cholesterol levels, the successful launch and customer demand for our Rē Muscle Health™ and other products, the continued growth of repeat purchases, market acceptance of our existing and future products, the ability to create new products through research and development, growth in our revenue, the successful entry into new markets including the age management market, the ability to collect our accounts receivable from our distributors, our ability to raise capital to fund continuing operations, the ability to attract additional investors and increase shareholder value, the ability to generate the forecasted revenue stream and cash flow from sales of Fortetropin® and Rē Muscle Health™, the ability to achieve a sustainable profitable business, the effect of economic conditions, the ability to protect our intellectual property rights, the ability to maintain and expand our manufacturing capabilities and reduce the costs of our products, the ability to comply with NASDAQ's continuing listing standards, competition from other providers and products, risks in product development, and other factors discussed from time to time in our Securities and Exchange Commission filings. We undertake no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.

MYOS Corporation Investor and Media Contact: Lindsey Penrose Vice President Business Development (973) 509-0444 Email Contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 119

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 411

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 378

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 423

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 0

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 585

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 481

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 259

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 407

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering Investors: The Launch of the CAPVX Fund Strategy

Updated Category News Views 227

Introduction to CAPVX Fund The Calamos Aksia Private Equity & Alternatives Fund, known as CAPVX, is a game-changer for investors looking to delve into the dynamic world of private equity. This innovative fund was launched by Calamos and Aksia, leveraging their combined expertise to provide a diversified portfolio that focuses on promising sectors within private equity...

Continue Reading
Celebrating Excellence: GFI Software 2025 Partner Awards

Updated Category News Views 158

Celebrating Excellence: GFI Software 2025 Partner Awards GFI Software is proud to highlight the achievements of its partners in the annual 2025 Partner Awards ceremony. As a global leader in AI-powered security and communications solutions tailored for small and medium-sized businesses (SMBs), GFI recognizes the pivotal role its partner network plays in driving growth and...

Continue Reading
Understanding the Growth of $100 Invested in KKR Over a Decade

Updated Category News Views 280

The Remarkable Growth of KKR Over the Past Decade Investing in KKR (NYSE: KKR) ten years ago would have been a smart move for any investor. Throughout this decade, KKR has consistently outperformed market expectations, achieving an impressive annualized return of 19.49%. This standout performance exceeds the market average by 8.29%, highlighting the potential of strategic...

Continue Reading
Luohu and Barcelona Forge a Path to Economic Cooperation

Updated Category News Views 460

Strengthening Economic Bonds: Luohu and Barcelona Unite In a remarkable display of international cooperation, Luohu has recently engaged with Barcelona, fostering productive dialogues in trade and economic development. Both cities are set to embark on a journey towards mutual growth and collaboration, marking the beginning of their shared objectives. The economic dynamics...

Continue Reading
Lantheus Welcomes Dr. Dinkelborg to Enhance R&D Following Acquisition

Updated Category News Views 363

Lantheus Completes Strategic Acquisition of Life Molecular Imaging Lantheus Holdings, Inc. (NASDAQ: LNTH) has achieved a significant milestone with the successful acquisition of Life Molecular Imaging Ltd., a move that underscores its commitment to expanding its impact in the field of radiopharmaceuticals. This strategic decision integrates advanced imaging capabilities...

Continue Reading